Hepatitis E Diagnostics Market By Test Type (ELISA HEV IgM Test kits, ELISA HEV IgG Test Kits, and RT-PCR Test Kits), By End User (Hospitals, Diagnostic Laboratories, Research Centers, and Point of Care), and By Region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa) - Trends, Analysis and Forecast till 2029

Hepatitis E diagnostics market accounted for USD 5.0 billion in 2020 and is projected to register a moderate CAGR of 6.6 % over the forecast period. 

Hepatitis E virus (HEV) is mainly responsible for the infection of acute viral hepatitis across the globe which directly affects on the liver. Hepatitis E virus directly transmitted by food and water contamination. Presence of viral RNA in the serum or faeces is the indication of presence of Hepatitis E Virus. For hepatitis E disease, there is no specific treatment has been developed yet. For Analysis of Hepatitis E virus, some biologic specimens such as stools and serum are used and which is performed on viral RNA. Liver biopsy is mainly used for the diagnosis of Hepatitis E Virus.

Major factors responsible for driving the growth of the hepatitis E diagnostic market are limited access to safe drinking water and poor sanitation which increases the incidence of liver Hepatitis E disease. In addition, rising scarcity of potable water, poor nutrition and government initiative regarding awareness are some among the major factors driving growth of the hepatitis E diagnosis market across the globe. However, high cost of diagnostics procedure and poor reimbursement policies are factors restraining growth of hepatitis E diagnostic market.

Hepatitis E Diagnostics Market has been segmented on the basis of test type, end user and region.

On the basis of test type, hepatitis E diagnostic market has been segmented into ELISA HEV IgM Test kits, ELISA HEV IgG Test Kits, and RT-PCR Test Kits. The end user segment includes hospitals, diagnostic laboratories, research centers, and point of care.

On the basis of region, hepatitis E diagnostic market has been segmented into North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. The market in Asia Pacific accounted for major share in hepatitis E diagnostic market in terms of revenue, owing to increasing incidence of hepatitis E disease in some countries of this region. High incidence rate of hepatitis E among the population in the countries of Asia pacific such as Vietnam, Pakistan, Bangladesh, Burma, Kazakhstan, Thailand, and Bhutan.

Key players operating in the hepatitis E diagnostic market includes F. Hoffmann-La Roche Ltd., Beijing Wantai Biological Pharmacy Enterprise Co.Ltd., Fast-track diagnostics Ltd., Altana Diagnostics GmbH, Fortress Diagnostics Ltd., Mikrogen GmBH, Abbott Laboratories, Siemens Ag, MP Biomedicals LLC, and Primerdesign Ltd.